Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Fagron SA ( (GB:0HNZ) ).
Fagron, a global leader in pharmaceutical compounding, has announced the acquisition of Guinama, a Spanish company known for repackaging and distributing active pharmaceutical ingredients. This strategic acquisition strengthens Fagron’s market position in the Iberian pharmaceutical compounding market and aligns with its growth strategy by enhancing its repackaging and distribution activities in Europe. The acquisition, valued at approximately €22 million, is expected to bring synergies through optimized sourcing and operations, further solidifying Fagron’s leadership in the region.
More about Fagron SA
Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in over 30 countries. It is registered in Belgium and listed on Euronext Brussels and Euronext Amsterdam, with operational activities managed from Rotterdam, The Netherlands.
YTD Price Performance: 14.87%
Average Trading Volume: 8,373
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €1.4B
For detailed information about 0HNZ stock, go to TipRanks’ Stock Analysis page.